In the in vivo Parkinson's disease model, García et al. (2018) found that PPARγ antagonist T0070907 (5 mg·kg−1) blocked VCE‐003.2‐mediated decreases in TNF‐α, IL‐1β, and iNOS mRNA levels, but no other antagonists were investigated. This evidence concerns the gene IL1B and Parkinson disease.